Outcomes
SHEP (1985)
BB + diuretico
com placebo
>60 anos com
PAS> 160
-13 mmHg
-36% de AVC
Syst- Eu
(1997)
IECA+BCC
com placebo
>60 anos com
PAS> 160
-10 mmHg
-31% de eventos
cardiovasculares
SCOPE
(2003)
ARA II +
diurético com
placebo
>70 anos
-3.2 mmHg
-28% de AVC
não fatais
HYVET
(2008)
IECA +
Diurético com
placebo
>80 anos
-15mmHg
-34% de eventos
cardiovasculares
43 TABELA IV
Tabela IV - Recomendações de valores alvo da HTA para a população idosa ESC/ESH 2018 e JNC8
Faixa etária anos PAS(mmHg) PAD( mmHg)
ESC/ESH 2018 >65 130-139 (se tolerado)
70-79 (se tolerado)
44 TABELA V
Classe Farmacológica Contraindicações
Absolutas Relativas
Diuréticos Gota Síndrome metabólica
Intolerância à glicose Hipercalcemia Hipocalémia
BCC (dihidropiridinas) Taquiarritmias
IC (FE reduzida)
Edema MI prévio severo
BCC (verapamil, diltiazem) Bloqueio Sino Auricular ou Auriculo Ventricular
Disfunção severa do VE Bradicardia
Obstipação
IECA Edema angioneurótico
Hipercalémia
Estenose da artéria renal bilateral
ARA II Hipercalémia
Estenose da artéria renal bilateral
BB Asma
Bloqueio Sino Auricular ou Auriculo Ventricular
Bradicardia
Sindrome Metabólica Intolerância à glicose
45
Referências Bibliográficas
1-World Population Prospects: The 2017 Revision | Multimedia Library - United Nations Department of Economic and Social Affairs;Un.org;disponível em: https://www.un.org/development/desa/publications/world-population-prospects-the-
2017.Consultado pela última vez em 2019/05/02.
2-Gil-Extremera B, Cía-Gómez P, Hypertension in the Elderly. Int J Hypertens. 2012;2012:1-4. 3-Rodrigues A. et al, Prevalência de hipertensão arterial em Portugal: resultados do Primeiro Inquérito Nacional com Exame Físico (INSEF 2015). Boletim Epidemiológico. 2017;6(9):1-4 4-Aronow WS, Lifestyle measures for treating hypertension. Arch Med Sci. 2017;13(5):1241– 1243.
5-Schmieder RE, End organ damage in hypertension. Dtsch Arztebl Int. 2010;107(49):866–873. 6-Parsons C, Mookadam F, Mookadam M, Hypertension treatment in the elderly: a SPRINT to the finish. Future Cardiol. 2017;13(2):99-102.
7-Lo SH, Chau JP, Woo J, Thompson DR, Choi KC, Adherence to Antihypertensive Medication in Older Adults With Hypertension. J Cardiovasc Nurs. 2016;31(4):296–303.
8-Williams B, Mancia G, Spiering W et al, 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104.
9-James P, Oparil S, Carter B et al, 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. JAMA. 2014;311(5):507.
10-Kaiser EA, Lotze U, Schäfer HH, Increasing complexity: which drug class to choose for treatment of hypertension in the elderly?. Clin Interv Aging. 2014;9:459–475.
11-Population ages 65 and above, (% of total); Data.worldbank.org. Disponível em: https://data.worldbank.org/indicator/SP.POP.65UP.TO?end=2017&start=1960&view=chart. Consultado pela última vez em 2019/05/10
12-PORDATA.Retrato de Portugal na Europa.2018.Lisboa: FFMS;2018
13-Forouzanfar M, Liu P, Roth G et al, Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mmHg, 1990-2015. JAMA. 2017;317(2):165.
14-Parati G, Stergiou G, Asmar R et al, European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens. 2008;26(8):1505-1526.
15-Ward AM, Takahashi O, Stevens R, Heneghan C, Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens. 2012;30:449–456
16-Tucker KL, Sheppard JP, Stevens R, et al, Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. PLoS Med. 2017;14(9):1-29. 17-Gaborieau V, Delarche N, Gosse P, Ambulatory blood pressure monitoring versus self- measurement of blood pressure at home: correlation with target organ damage. J Hypertens. 2008;26:1919–1927.
46 18-Banegas JR, Ruilope LM, de la Sierra A, et al, Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med. 2018;378:1509–1520.
19-Bolívar JJ, Essential hypertension: an approach to its etiology and neurogenic pathophysiology. Int J Hypertens. 2013;2013:1-7.
20-Carey R, Calhoun D, Bakris G et al, Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018;72(5):7-16.
21-Gupta P, Patel P, Štrauch B et al, Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension. 2017;70(5):1042- 1048.
22-Judd E, Calhoun DA, Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014;28(8):463–468.
23-Puar TH, Mok Y, Debajyoti R, Khoo J, How CH, Ng AK, Secondary hypertension in adults. Singapore Med J. 2016;57(5):228–232.
24-Bavishi C, Goel S, Messerli F, Isolated Systolic Hypertension: An Update After SPRINT. Am J Med. 2016;129(12):1251-1258.
25-Mancia G, Bombelli M, Cuspidi C, Facchetti R, Grassi G, Cardiovascular Risk Associated With White-Coat Hypertension. Hypertension. 2017;70(4):668-675
26-Beevers G, Lip GY, O'Brien E, ABC of hypertension: The pathophysiology of hypertension. BMJ. 2001;322(7291):912–916.
27-Seals DR, Jablonski KL, Donato AJ, Aging and vascular endothelial function in humans. Clin Sci (Lond). 2011;120(9):357–375.
28-Hall, J., Granger, J., do Carmo, J et al, Hypertension: Physiology and Pathophysiology. Comprehensive Physiology. 2012;2(4): 2393-2442
29-Fisher, J., & Paton, J., The sympathetic nervous system and blood pressure in humans: implications for hypertension. Journal Of Human Hypertension.2011;26(8):463-475.
30-Lionakis N, Mendrinos D, Sanidas E, Favatas G, Georgopoulou M, Hypertension in the elderly. World J Cardiol. 2012;4(5):135–147.
31-Nadar SK, Tayebjee MH, Messerli F, Lip GY, Target organ damage in hypertension: pathophysiology and implications for drug therapy. Curr Pharm Des. 2006; 12(13):1581-1592. 32-Ramli A, Ahmad NS, Paraidathathu T, Medication adherence among hypertensive patients of primary health clinics in Malaysia. Patient Prefer Adherence. 2012; 6():613-622.
33-Lawler PR, Hiremath P, Cheng S, Cardiac target organ damage in hypertension: insights from epidemiology. Curr Hypertens Rep. 2014;16(7):446.
34-Kasper, Dennis L., et al. Harrison's Principles of Internal Medicine. 19ª edição. New York: McGraw Hill Education; 2015.
35-Bidani AK, Griffin KA, Basic science: hypertensive target organ damage. J Am Soc Hypertens. 2015;9(3):235–238.
36-Meissner A,Hypertension and the Brain: A Risk Factor for More Than Heart Disease. Cerebrovasc Dis. 2016;42:255-262.
47 37-McDonald C, Pearce MS, Kerr SR, et al, Blood pressure variability and cognitive decline in older people: a 5-year longitudinal study. J Hypertens. 2017;35:140-147.
38-Aronow WS, Hypertension and cognitive impairment. Ann Transl Med. 2017;5(12):259. 39-Mahoney J, Verghese J, Goldin Y, Lipton R, Holtzer R, Alerting, orienting, and executive attention in older adults. Journal of the International Neuropsychological Society. 2010;16(5):877-889.
40- Webster A, Nagler E, Morton R, Masson P, Chronic Kidney Disease. The Lancet. 2017;389(10075):1238-1252.
41-Judd E, Calhoun DA, Management of hypertension in CKD: beyond the guidelines. Adv Chronic Kidney Dis. 2015;22(2):116–122.
42-Mulè G, Castiglia A, Cusumano C et al, Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria. Adv Exp Med Biol. 2016:279-306.
43-Virdis A, Bruno RM, Neves MF, Bernini G, Taddei S, Ghiadoni L, Hypertension in the elderly: an evidence-based review. Curr Pharm Des; 2011. 17(28):3020-31.
44-Modi P, Arsiwalla T. Hypertensive Retinopathy. Flórida: StatPearls Publishing; Disponível em: https://www.ncbi.nlm.nih.gov/books/NBK525980/. Consultado pela última vez: 2019/05/13 45-Sankar PS, O'Keefe L, Choi D, et al, The SCHEIE Visual Field Grading System. J Clin Exp Ophthalmol. 2017;8(3):651.
46-Ettehad D, Emdin C, Kiran A et al, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387(10022):957- 967.
47-Thomopoulos C, Parati G, Zanchetti A, Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32(12):2285-2295.
48-Lv J, Ehteshami P, Sarnak M et al, Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. Can Med Assoc J. 2013;185(11):949-957.
49-Virdis A, Giannarelli C, Fritsch Neves M, Taddei S, Ghiadoni L, Cigarette Smoking and Hypertension.CurrPharmDes.2010;16(23):2518-2525.
50-Kotseva K, Wood D, De Bacquer D et al, EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2015;23(6):636-648.
51-Primatesta P, Falaschetti E, Gupta S, Marmot MG, Poulter NR, Association between smoking and blood pressure: evidence from the health survey for England. Hypertension. 2001;37:187– 193
52-Virdis A, M. Bruno R, Fritsch Neves M, Bernini G, Taddei S, Ghiadoni L, Hypertension in the Elderly: An Evidence-based Review. Curr Pharm Des. 2011;17(28):3020-3031.
53-Cahill K, Stevens S, Perera R, Lancaster T, Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database of Systematic Reviews. 2013;5:1-4.
48 55-Cohen JB, Hypertension in Obesity and the Impact of Weight Loss. Curr Cardiol Rep. 2017;19(10):98.
56-Neter J, Stam B, Kok F, Grobbee D, Geleijnse J, Influence of Weight Reduction on Blood Pressure. Hypertension. 2003;42(5):878-884.
57-Aronow WS, Association of obesity with hypertension. Ann Transl Med. 2017;5(17):350. 58-Elliott P, Stamler J, Nichols R et al, Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. BMJ. 1996;312(7041):1249-1253. 59-He F, Li J, MacGregor G, Effect of longer-term modest salt reduction on blood pressure. Cochrane Database of Systematic Reviews. 2013;346:1-15.
60-Samadian, F., Dalili, N., & Jamalian, A, Lifestyle modifications to prevent and control hypertension. Iranian journal of kidney diseases. 2016;10(5), 243.
61-Adler AJ, Taylor F, Martin N, Gottlieb S, Taylor RS, Ebrahim S, Reduced dietary salt for the prevention of cardiovascular disease. Cochrane Database Syst. 2014(12):15-16
62-Mateti U, Vooradi S, A systemic review on lifestyle interventions to reduce blood pressure. Journal of Health Research and Reviews. 2016;3(1):1
63-Cornelissen VA, Smart NA, Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2(1):1-9.
64-Cushman WC, Cutler JA, Hanna E, et al, Prevention and Treatment of Hypertension Study (PATHS): effects of an alcohol treatment program on blood pressure. Arch Intern Med. 1998;158:1197–1207
65-Holmes M, Dale C, Zuccolo L et al, Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2014;349:1-7 66- The SPRINT Research Group, A Randomized Trial of Intensive versus Standard Blood- Pressure Control. New England Journal of Medicine. 2015;373(22):2103-2116.
67-Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. JAMA. 1991;265(24):3255.
68-Staessen J, Fagard R, Thijs L et al, Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet. 1997;350(9080):757-764.
69-Lithell H, Hansson L, Skoog I et al, The Study on Cognition and Prognosis in the Elderly (SCOPE). J Hypertens. 2003;21(5):875-886.
70-Beckett N, Peters R, Fletcher A et al, Treatment of Hypertension in Patients 80 Years of Age or Older. New England Journal of Medicine. 2008;358(18):1887-1898.
71-Chen P, Chaugai S, Zhao F, Wang D, Cardioprotective Effect of Thiazide-Like Diuretics: A Meta- Analysis. Am J Hypertens. 2015;28(12):1453-1463
72-Duarte JD, Cooper-DeHoff RM, Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther. 2010;8(6):793–802. 73-Nguyen QT, Anderson SR, Sanders L, Nguyen LD, Managing hypertension in the elderly: a common chronic disease with increasing age. Am Health Drug Benefits. 2012;5(3):146–153.
49 74-Kithas PA, Supiano MA, Practical recommendations for treatment of hypertension in older patiens. Vasc Health Risk Manag; 2010;6:561-569.
75-Tocci G, Desideri G, Roca E, et al, How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension. High Blood Press Cardiovasc Prev. 2017;25(1):25–34.
76-Oparil S, Acelajado MC, Bakris GL, et al, Hypertension. Nat Rev Dis Primers. 2018;4:16-19. 77-Lonn EM, Bosch J, Lopez-Jaramillo P, et al, on behalf of the HOPE-3 Investigators. Blood- Pressure Lowering in Intermediate-Risk Persons Without Cardiovascular Disease. N Engl J Med.2016;374(21):2009-2020
78-Port S, Demer L, Jennrich R, Walter D, Garfinkel A, Systolic blood pressure and mortality. Lancet. 2000; 355:175-180.
79-Briasoulis A, Agarwal V, Tousoulis D, Stefanadis C, Effects of antihypertensive treatment in patients over 65 years of age: a meta-analysis of randomised controlled studies. Heart. 2014; 100:317-323.
80-Peters R, Beckett N, McCormack T, Fagard R, Fletcher A, Bulpitt C,Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. Eur Heart J. 2014;35:1712-1718.
81-Mori Y, Nishikawa Y, Iizuka T, et al, Artist(R) tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey. Drugs R D. 2011, 11:171-190.
82-Atkins E, Hirakawa Y, Salam A et al, Side effects and tolerability of combination blood pressure lowering according to blood pressure levels. J Hypertens. 2017;35(6):1318-1325. 83-Bromfield SG, Ngameni CA, Colantonio LD, et al, Blood Pressure, Antihypertensive Polypharmacy, Frailty, and Risk for Serious Fall Injuries Among Older Treated Adults With Hypertension. Hypertension. 2017;70(2):259–266.
84-Shimbo D, Barrett Bowling C, Levitan EB, et al, Short-Term Risk of Serious Fall Injuries in Older Adults Initiating and Intensifying Treatment With Antihypertensive Medication. Circ Cardiovasc
Qual Outcomes. 2016;9(3):222–229.
85-Klein D, Nagel G, Kleiner A, et al, Blood pressure and falls in community-dwelling people aged 60 years and older in the VHM&PP cohort. BMC Geriatr. 2013;13:50.
86-Tinetti ME, Han L, Lee DS, et al, Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med. 2014;174(4):588–595. 87-Dharmarajan T, Dharmarajan L, Tolerability of Antihypertensive Medications in Older Adults. Drugs Aging. 2015;32(10):773-796.
88-Weiss J, Freeman M, Low A et al, Benefits and Harms of Intensive Blood Pressure Treatment in Adults Aged 60 Years or Older. Ann Intern Med. 2017;166(6):419.
89- Mukhtar O, Jackson SH, Risk: benefit of treating high blood pressure in older adults. Br J Clin Pharmacol. 2013;75:36-44.
90-Bokrantz T, Ljungman C, Kahan T et al, Thiazide diuretics and the risk of osteoporotic fractures in hypertensive patients. Results from the Swedish Primary Care Cardiovascular Database. J
50 91-Peters R, Beckett N, McCormack T, Fagard R, Fletcher A, Bulpitt C,Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. Eur Heart J. 2014;35(26):1712–1718.
92-Elliott W, Ram C,Calcium Channel Blockers. The Journal of Clinical Hypertension. 2011;13(9):687-689
93-George C. Roush, Domenic A, Sica, Diuretics for Hypertension: A Review and Update,
American Journal of Hypertension. 2016;29(10):1130–1137
94-Carone L, Oxberry S, Twycross R, et al, J Pain Symptom Manage. 2017;53(2):288-292. 95-Sica D, Diuretic‐Related Side Effects: Development and Treatment. The Journal of Clinical Hypertension. 2004;6(9):532-540.
96-Aronow W, Fleg J, Pepine C et al, ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. J Am Coll Cardiol. 2011;57(20):2037-2114.
97-Shruthi R, Jyothi R, Pundarikaksha HP, Nagesh GN, Tushar TJ, A Study of Medication Compliance in Geriatric Patients with Chronic Illnesses at a Tertiary Care Hospital. J Clin Diagn
Res. 2016;10(12):40–43.
98-Chrostowska M, Narkiewicz K, Improving patient compliance with hypertension treatment: mission possible? Curr Vasc Pharmacol. 2010; 8:804-80.
99-Uchmanowicz B, Chudiak A, Uchmanowicz I, Rosińczuk J, Froelicher ES, Factors influencing adherence to treatment in older adults with hypertension. Clin Interv Aging. 2018;13:2425– 2441.
100-Thoenes M, Spirk D, Bohm M, Mahfoud F, Thevathasan L, Bramlage P, Treatment of hypertension in the elderly: data from an international cohort of hypertensives treated by cardiologists. J Hum Hypertens. 2013; 27:131-137.
101-Mukete B, Ferdinand K, Polypharmacy in Older Adults With Hypertension: A Comprehensive Review. The Journal of Clinical Hypertension. 2015;18(1):10-18.
102-Naderi S, Bestwick J, Wald D, Adherence to Drugs That Prevent Cardiovascular Disease: Meta-analysis on 376,162 Patients. Am J Med. 2012;125(9):882-887.e1.
103-Kim S, Shin D, Yun J et al, Medication Adherence and the Risk of Cardiovascular Mortality and Hospitalization Among Patients With Newly Prescribed Antihypertensive Medications.